Recently released market study: Vaccines Market Access in India - New vaccine uptake drives growth

July 14, 2012 - PRLog -- The government-sponsored Universal Immunization Program procures vaccines at very low prices, predominantly from local manufacturers. There also exists a large private market for vaccines which is dominated by multinational companies. The private market for newer and better vaccines is growing due to the increasing affordability of the middle class population.

Report Scope

* Review the current regulatory processes, pricing mechanisms, and vaccination schedule in India.
* Identify major multinational and domestic players, view their product portfolios and pipelines, and understand their expansion strategies.
* Examine the major drivers and resistors of the current Indian vaccine market and understand the key opportunities and threats facing developers.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/434384_vaccines_market_access_in_india_new_vaccine.aspx
------------------------------------------------------------

Report Highlights

India is the world's largest producer of vaccines: 60% of the world's vaccines are manufactured in the country and it accounts for 60-80% of annual UN vaccine purchases. The Indian government spends more than INR20bn ($400m) every year to immunize children against several vaccine-preventable diseases.

In India, there are two different immunization schedules: the National Immunization Schedule, published by the Indian government, and the "best individual practices schedule," published by the Indian Academy of Pediatrics. The latter includes additional vaccines and varies from the National Immunization Schedule.

GlaxoSmithKline is the leading multinational company, while Serum Institute of India and Panacea Biotec outperform their domestic counterparts. Indian vaccine manufacturers also supply UN agencies and export vaccines to many countries. Western companies are forming strategic alliances or acquiring domestic companies to expand their market presence

Reasons to Get this Report

* What are the two different immunization schedules followed in India and what are the vaccines included in them?
* What is the regulatory process of vaccine development? What is the pricing and reimbursement process of vaccines in India?
* Which are the key domestic and multinational companies active in vaccine development?
* What deals and alliances are shaping the Indian vaccine market?

Partial Table of Contents:

OVERVIEW

* Catalyst
* Summary

EXECUTIVE SUMMARY

* Scope of the analysis
* Datamonitor insight into the Indian vaccines market
* Related reports

MARKET OVERVIEW

* Historic development

* Vaccine policy in India post-independence

* Current market situation
* Regulatory process for vaccines
* Vaccination recommendations

* Introduction of new vaccines in the NIS and IAP recommendations

* Vaccine pricing

* Pricing of vaccines included in the UIP
* Pricing of optional vaccines that are not included in the UIP

* Vaccine reimbursement
* Vaccine distribution and access
* Vaccination coverage

KEY COMPANIES ACTIVE IN THE INDIAN VACCINES MARKET

* Key findings
* Industry overview

* General overview

* Multinational vaccine companies in India

* GlaxoSmithKline
* Merck Sharp & Dohme
* Novartis
* Sanofi Pasteur

* Domestic vaccine companies

* Bharat Biotech
* Biological E
* Bio-Med
* Indian Immunologicals
* Panacea Biotec
* Serum Institute of India

STRATEGIC RECOMMENDATIONS FOR MARKET ACCESS

* Key findings
* Key future target indications
* SWOT analysis of India as a target market for vaccines
* Drivers and resistors

* Drivers
* Resistors

* Best strategy for market penetration

* Partnership with local companies will help multinationals increase their market coverage
* Setting up of vaccine manufacturing facility in India will be advantageous
* Inclusion of new vaccines into the immunization schedule is critical for domestic and Western vaccine manufacturers

BIBLIOGRAPHY

* Journals
* Websites
* Datamonitor reports

APPENDIX

* Contributing experts
* Conferences attended
* Report methodology

TABLES

* Table: India: estimated number of vaccine doses distributed for key indications, 2010
* Table: Price of optional vaccines in the Indian private sector, 2011
* Table: Vaccination recommendations and reimbursement status in India, 2011
* Table: Biotech sales of key vaccine players in India ($m), 2011
* Table: Vaccine portfolio of multinational companies in India, 2011
* Table: Vaccine portfolio of domestic companies, 2011
* Table: GlaxoSmithKline: human vaccine portfolio and pipeline overview in India, 2011
* Table: Merck Sharp & Dohme: human vaccine portfolio and pipeline overview in India, 2011
* Table: Merck Sharp & Dohme: key vaccine deals and alliances in India, 2011
* Table: Novartis: human vaccine portfolio and pipeline overview in India, 2011
* Table: Novartis: key vaccine deals and alliances in India, 2011
* Table: Sanofi: human vaccine portfolio and pipeline overview in India, 2011
* Table: Sanofi: key vaccine deals and alliances in India, 2011
* Table: Bharat Biotech: human vaccine portfolio and pipeline overview, 2011
* Table: Bharat Biotech: key vaccine deals and alliances, 2011
* Table: Biological E: human vaccine portfolio and pipeline overview, 2011
* Table: Biological E: key vaccine deals and alliances, 2011
* Table: Bio-Med: human vaccine portfolio and pipeline overview, 2011
* Table: Indian Immunologicals: human vaccine portfolio and pipeline overview, 2011
* Table: Panacea Biotec (including Chiron Panacea): human vaccine portfolio and pipeline overview, 2011
* Table: Panacea Biotec: key vaccine deals and alliances, 2011
* Table: Serum Institute of India: human vaccine portfolio and pipeline overview, 2011
* Table: Serum Institute of India: key vaccine deals and alliances, 2011
* Table: Shantha Biotech: human vaccine portfolio and pipeline overview, 2011
* Table: Shantha Biotech: key vaccine deals and alliances, 2011
* Table: SWOT analysis of the Indian vaccines market, 2011
* Table: India versus selected countries: National immunization Schedule comparison, 2011
* Table: Key partnerships of multinational corporation with local vaccine players in India, 2011

FIGURES

* Figure: Timeline of vaccine development in India, 1960-2005
*

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=4343...

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.